紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展

朱鋆芳; 高敬林; 赵浩鹏; 郄宏鑫; 高笑男; 王明霞

doi:10.6039/j.issn.1001-0408.2024.03.19

您当前的位置：

首页 >

文章列表页 >

紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展

综述 | 更新时间：2024-02-07

- 紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展
- Advances in influential factor and drug treatment studies for taxane-induced peripheral neuropathy
- 中国药房 2024年35卷第3期页码：374-378
- 作者机构：
  
  1.河北医科大学第四医院临床药理研究部，石家庄　050011
  2.河北省肿瘤微环境与耐药重点实验室，石家庄　050011
- 作者简介：
  
  硕士研究生。研究方向：肿瘤药物临床药理学。 E-mail：20212411@stu.hebmu.edu.cn
  主任药师，博士生导师，博士。研究方向：肿瘤药物临床药理学。电话：0311-66696233
- 基金信息：
  
  国家科技重大专项(2020ZX09201006-003);河北省自然科学基金项目(H2021206432);河北省2020年度医学科学研究课题(20200105)
- DOI：10.6039/j.issn.1001-0408.2024.03.19
  中图分类号： R979.1;R969.3
- 纸质出版日期：2024-02-15，
  
  收稿日期：2023-07-07，
  
  修回日期：2023-11-20，
扫描看全文
朱鋆芳,高敬林,赵浩鹏等.紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展 ^Δ[J].中国药房,2024,35(03):374-378.

ZHU Yunfang,GAO Jinglin,ZHAO Haopeng,et al.Advances in influential factor and drug treatment studies for taxane-induced peripheral neuropathy[J].ZHONGGUO YAOFANG,2024,35(03):374-378.
朱鋆芳,高敬林,赵浩鹏等.紫杉类药物诱发周围神经病变的影响因素及药物治疗研究进展 ^Δ[J].中国药房,2024,35(03):374-378. DOI： 10.6039/j.issn.1001-0408.2024.03.19.

ZHU Yunfang,GAO Jinglin,ZHAO Haopeng,et al.Advances in influential factor and drug treatment studies for taxane-induced peripheral neuropathy[J].ZHONGGUO YAOFANG,2024,35(03):374-378. DOI： 10.6039/j.issn.1001-0408.2024.03.19.

摘要

紫杉类药物诱发的周围神经病变（TIPN）患者已达数百万例，且临床尚无有效的治疗手段或预防措施。TIPN的发生可能与紫杉类药物剂型、遗传和分子标志物、药物剂量及化疗周期、患者因素等有关。目前，治疗TIPN的药物主要包括抑制轴突变性类（如多沙唑嗪、坦索罗辛）、阻止线粒体功能受损类（如谷胱甘肽三硫化物、抗氧化剂

-硫辛酸）、改善内环境中钙失衡类（如芍药甘草汤、N型电压门控钙通道抑制剂IPPQ）、抑制神经炎症类（如趋化因子抑制剂、选择性白细胞介素8受体抑制剂DF2726A）等。未来进一步探索对症于不同诱发机制的药物治疗策略有望成为临床精准防治及个体化治疗TIPN的新方向。

Abstract

There are millions of patients with taxane-induced peripheral neuropathy （TIPN）， and there is no effective treatment or prevention measure in clinical practice. The occurrence of TIPN may be related to the dosage form of paclitaxel drugs， genetic and molecular markers， drug dosage and chemotherapy cycle， patient factors， etc. At present， drugs for treating TIPN mainly include those that inhibit axonal degeneration （such as dosazosin， tamsulosin）， prevent mitochondrial dysfunction （such as glutathione trisulfides， antioxidants

-lipoic acid）， improve calcium imbalance in the internal environment （Shaoyao gancao decoction， N-type voltage-gated calcium channel inhibitor IPPQ）， and inhibit neuroinflammation （such as chemokine inhibitors and selective interleukin-8 receptor inhibitors DF2726A）. Further exploration of drug treatment strategies targeting different induction mechanisms is expected to become a new direction for precise clinical prevention and personalized treatment of TIPN.

关键词

紫杉类药物周围神经病变影响因素治疗药物

Keywords

peripheral neuropathyinfluential factortherapeutic drug

references

TRECARICHI A，FLATTERS S J L. Mitochondrial dysfunction in the pathogenesis of chemotherapy-induced peripheral neuropathy[J]. Int Rev Neurobiol，2019，145：83-126.

MAHNER S，MEIER W，BOIS A D，et al. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients：results from a subset analysis of the CALYPSO phase Ⅲ trial[J]. Eur J Cancer，2015，51（3）：352-358.

VAN CUTSEM E，MOISEYENKO V M，TJULANDIN S，et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer：a report of the V325 study group[J]. J Clin Oncol，2006，24（31）：4991-4997.

马飞，刘明生，王佳妮，等. 紫杉类药物相关周围神经病变规范化管理专家共识[J]. 中国医学前沿杂志（电子版），2020，12（3）：41-51.

MA F，LIU M S，WANG J N，et al. Expert consensus on standardized management of taxane-related peripheral neuropathy[J]. Chin J Front Med Sci Electron Version，2020，12（3）：41-51.

LOPRINZI C L，LACCHETTI C，BLEEKER J，et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers：ASCO guideline update[J]. J Clin Oncol，2020，38（28）：3325-3348.

胡嘉芮，樊捷婷，何晓华，等. 紫杉醇致周围神经病变的研究进展[J]. 中国新药与临床杂志，2023，42（10）：616-621.

HU J R，FAN J T，HE X H，et al. Research progress of peripheral neuropathy caused by paclitaxel[J]. Chin J N Drugs Clin Remedies，2023，42（10）：616-621.

MO H N，YAN X Y，ZHAO F，et al. Association of taxane type with patient-reported chemotherapy-induced periphe- ral neuropathy among patients with breast cancer[J]. JAMA Netw Open，2022，5（11）：e2239788.

BOORA G K，KANWAR R，KULKARNI A A，et al. Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 （Alliance）[J]. Cancer Med，2016，5（4）：631-639.

HERTZ D L，ROY S，JACK J，et al. Genetic heterogenei- ty beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy[J]. Breast Cancer Res Treat，2014，145（1）：245-254.

CHEN Y Z，FANG F，KIDWELL K M，et al. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy[J]. Pharmacogenomics，2020，21（12）：841-851.

APELLÁNIZ-RUIZ M，TEJERO H，INGLADA-PÉREZ L，et al. Targeted sequencing reveals low-frequency variants in EPHA genes as markers of paclitaxel-induced peripheral neuropathy[J]. Clin Cancer Res，2017，23（5）：1227-1235.

SCHNEIDER B，LI L，MIILLER K，et al. Genetic associations with taxane-induced neuropathy by a genome-wide association study （GWAS） in E5103[J]. Clin Oncol，2011，29 （15_suppl）：1000.

CUNNINGHAM G M，SHEN F，WU X，et al. The impact of SBF2 on taxane-induced peripheral neuropathy[J]. PLoS Genet，2022，18（1）：e1009968.

BOSANAC T，HUGHES R O，ENGBER T，et al. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy[J]. Brain，2021，144（10）：3226-3238.

GILLEY J，MAYER P R，YU G，et al. Low levels of NMNAT2 compromise axon development and survival[J]. Hum Mol Genet，2019，28（3）：448-458.

CATALANO M，RAMELLO M，CONCA R，et al. Risk factors for nab-paclitaxel and gemcitabine-induced peripheral neuropathy in patients with pancreatic cancer[J]. Oncology，2022，100（7）：384-391.

GUO Q，ZHANG H N，LI X，et al. Risk factors for chemotherapy-induced peripheral neuropathy caused by nanoparticle albumin-bound paclitaxel in advanced breast cancer[J]. Biomed Res Int，2022，2022：9430952.

BIGANZOLI L，CINIERI S，BERARDI R，et al. EFFECT：a randomized phase Ⅱ study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer[J]. Breast Cancer Res，2020，22（1）：83.

HIRAMOTO S，ASANO H，MIYAMOTO T，et al. Risk factors and pharmacotherapy for chemotherapy-induced peripheral neuropathy in paclitaxel-treated female cancer survivors：a retrospective study in Japan[J]. PLoS One，2021，16（12）：e0261473.

RIVERA E，CIANFROCCA M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer[J]. Cancer Chemother Pharmacol，2015，75（4）：659-670.

SCHNEIDER B P，ZHAO F M，WANG M L，et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer[J]. J Clin Oncol，2012，30（25）：3051-3057.

HIRSH V，KO A，PILOT R，et al. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer：analysis of safety and efficacy in patients with diabetes[J]. Clin Lung Cancer，2016，17（5）：367-374.

BAE E H，GREENWALD M K，SCHWARTZ A G. Chemotherapy-induced peripheral neuropathy：mechanisms and therapeutic avenues[J]. Neurotherapeutics，2021，18（4）：2384-2396.

MORI K，KAWASHIRI T，MINE K，et al. Inhibitory effect of α1 receptor antagonists on paclitaxel-induced peripheral neuropathy in a rodent model and clinical database[J]. Toxics，2022，10（11）：669.

CIRRINCIONE A M，PELLEGRINI A D，DOMINY J R，et al. Paclitaxel-induced peripheral neuropathy is caused by epidermal ROS and mitochondrial damage through conserved MMP-13 activation[J]. Sci Rep，2020，10（1）：3970.

EZAKA M，MARUTANI E，MIYAZAKI Y，et al. Oral administration of glutathione trisulfide increases reactive sulfur levels in dorsal root ganglion and ameliorates paclitaxel-induced peripheral neuropathy in mice[J]. Antioxidants （Basel），2022，11（11）：2122.

SUN H，GUO X，WANG Z T，et al. Alphalipoic acid prevents oxidative stress and peripheral neuropathy in nab-paclitaxel-treated rats through the Nrf2 signalling pathway[J]. Oxid Med Cell Longev，2019，2019：3142732.

MIRONOV S L，IVANNIKOV M V，JOHANSSON M. [Ca2+]i signaling between mitochondria and endoplasmic reticulum in neurons is regulated by microtubules. From mitochondrial permeability transition pore to Ca2+-induced Ca2+ release[J]. J Biol Chem，2005，280（1）：715-721.

CHEN Y，LU R，WANG Y，et al. Shaoyao gancao decoction ameliorates paclitaxel-induced peripheral neuropathy via suppressing TRPV1 and TLR4 signaling expression in rats[J]. Drug Des Devel Ther，2022，16：2067-2081.

ADAMEK P，HELES M，BHATTACHARYYA A，et al. Dual PI3Kδ/γ inhibitor duvelisib prevents development of neuropathic pain in model of paclitaxel-induced peripheral neuropathy[J]. J Neurosci，2022，42（9）：1864-1881.

KHANNA R，YU J，YANG X F，et al. Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy[J]. Pain，2019，160（7）：1644-1661.

FLATTERS S J L，DOUGHERTY P M，COLVIN L A. Clinical and preclinical perspectives on Chemotherapy-Induced Peripheral Neuropathy （CIPN）：a narrative review[J]. Br J Anaesth，2017，119（4）：737-749.

BRANDOLINI L，CASTELLI V，ARAMINI A，et al. DF2726A，a new IL-8 signalling inhibitor，is able to counteract chemotherapy-induced neuropathic pain[J]. Sci Rep，2019，9（1）：11729.

KARMAKAR V，MOHAMMAD F S，BAEESA S S，et al. Effect of cliothosa aurivilli on paclitaxel-induced peripheral neuropathy in experimental animals[J]. Mol Neurobiol，2022，59（4）：2232-2245.

PETROSINO S，SCHIANO MORIELLO A. Palmitoylethanolamide：a nutritional approach to keep neuroinflammation within physiological boundaries：a systematic review[J]. Int J Mol Sci，2020，21（24）：9526.

SILVA R V，OLIVEIRA J T，SANTOS B L R，et al. Long-chain omega-3 fatty acids supplementation accelerates nerve regeneration and prevents neuropathic pain behavior in mice[J]. Front Pharmacol，2017，8：723.

ZAISS M，UHLIG J，ZAHN M O，et al. Improving chemotherapy-induced peripheral neuropathy in patients with breast or colon cancer after end of （neo）adjuvant therapy：results from the observational study STEFANO[J]. Oncol Res Treat，2021，44（11）：613-621.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

阿尔茨海默病的发病机制及治疗药物研究进展

脑缺血再灌注损伤药物治疗的研究进展

药物基因组学在心血管疾病药物治疗中的研究进展

类风湿性关节炎的发病机制及治疗药物研究进展